Haiqing Hua

Efficacy and safety of camrelizumab combined with apatinib as second‐line and beyond treatment for advanced combined hepatocellular‐cholangiocarcinoma

Haiyun Geng, Fang Dai, Kuimin Mei, Mengran Cao et autres

Abstract Objective To investigate the efficacy and safety of camrelizumab plus apatinib as second‐line and beyond treatment for advanced combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA), and to identify prognostic factors. Methods Patients with advanced cHCC‐CCA receiving camrelizumab (200 mg, IV, q3w) plus apatinib (250 mg, …

cn (code pays fourni par la source)

Abstract A132: DB-1317, a novel ADAM9-targeting antibody-drug conjugate, exhibits potent antitumor activity against multiple gastrointestinal cancers

Shengchao Lin, Jun Yao, Junjie Yang, Rong Shi et autres

Abstract Background: A disintegrin and metalloproteinase 9 (ADAM9) is highly expressed in various gastrointestinal cancers, and its expression level correlates with suppressive tumor microenvironment, metastasis and poor prognosis. DB-1317 is a novel ADAM9-targeting ADC with a topoisomerase inhibitor payload P1003 at drug-antibody …

Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models

Yunhua Zhou, Jun Yao, Rong Shi, Yang Qiu et autres

Background: EGFR and HER3 are co-overexpressed in a spectrum of tumors, including lung, breast, gastrointestinal, renal cell, ovarian, bladder, and prostate cancers. Importantly, HER3 expression is further enhanced upon inhibition of EGFR, suggesting that simultaneous targeting of both EGFR and HER3 could …

cn (code pays fourni par la source)

Abstract 5454: DB-1325, a BCMA-targeting antibody-drug conjugate with a Duality Unique Payload, exhibits promising efficacy and safety in preclinical multiple myeloma treatment

Shengchao Lin, Bing Li, Yu Zhang, Jun Ping Yao et autres

Introduction: B cell maturation antigen (BCMA) overexpression has been found on the surface of the malignant plasma cells in the bone marrow of multiple myeloma (MM) patients. In recent years, innovative medicines targeting BCMA such as antibody-drug conjugates (ADC), T-cell engager and …

cn (code pays fourni par la source)

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer

Xi Li, Liwen Liang, Zhongyuan Zhu, Haiqing Hua et autres

HER3 overexpression has been described in patients with HER2-positive BC[1][1]. We determined the levels of HER2 and HER3 expression in BC using RNA-seq data from 1,082 BC patient samples in the TCGA dataset and 67 BC cell lines in the CCLE database …

cn (code pays fourni par la source)

DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models

Shengchao Lin, Yu Long Zhang, Jun Yao, Junjie Yang et autres

BACKGROUND: Delta-like ligand 3 (DLL3) is highly expressed on the cell surface of small cell lung cancer (SCLC), one of the most lethal malignancies, but minimally or not in normal tissues, making it an attractive target for SCLC. However, none of the …

cn (code pays fourni par la source)

DB-2304, a Duality Immune Modulating Antibody‒Drug Conjugate (DIMAC) targeting BDCA2, displays strong potency in the suppression of pDC functions.

Xi Li, Bing Li, Jun Ping Yao, Rong Shi et autres

Abstract Study Objective: BDCA2 is specifically expressed on plasmacytoid dendritic cells (pDCs), whose overproduction of type I IFN is crucial in SLE pathogenesis. Combining anti-BDCA2 mAB with glucocorticoids (GCs) has shown clinical efficacy. Previous studies revealed superior anti-inflammatory effects of anti-BDCA2 antibody‒drug …

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

Xi Li, Jun Yao, Qu Chen, Lan Luo et autres

BACKGROUND: HER3 (ErbB3), a member of the human epidermal growth factor receptor family, is frequently overexpressed in various cancers. Multiple HER3-targeting antibodies and antibody-drug conjugates (ADCs) were developed for the solid tumor treatment, however none of HER3-targeting agent has been approved for …

cn (code pays fourni par la source)

An immunomodulatory antibody–drug conjugate targeting BDCA2 strongly suppresses plasmacytoid dendritic cell function and glucocorticoid responsive genes

Xi Li, Yu Zhang, Bing Li, Jian Li et autres

OBJECTIVES: Blood dendritic cell antigen 2 (BDCA2) is exclusively expressed on plasmacytoid dendritic cells (pDCs) whose uncontrolled production of type I IFN (IFN-I) is crucial in pathogenesis of SLE and other autoimmune diseases. Although anti-BDCA2 antibody therapy reduced disease activity in SLE …

cn (code pays fourni par la source)

Abstract 1884: DB-1310, a novel Her3 targeting antibody-drug conjugate, exhibits therapeutic efficacy for solid tumors

Xi Li, Jun Ping Yao, Qu Chen, Lan Luo et autres

Abstract Background: HER3 (ErbB3), a member of the human epidermal growth factor receptor family, is frequently overexpressed in various cancers. Its high expression is associated with poor prognosis in several solid tumors. Many anti-Her3 antibodies have been developed for cancer therapy. To …

Abstract 2793: Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-targeting antibody-drug conjugate

Rong Shi, Shengchao Lin, Yu Zhang, Bing Li et autres

Abstract Background: DB-1303 is a novel antibody-drug conjugate comprised of trastuzumab biosimilar, enzymatically cleavable peptide-linker, and a proprietary topoisomerase I inhibitor P1003. It is designed to have high plasma stability, low free payload in circulation and wide therapeutic index. Herein, the preclinical …

Abstract 2967: Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors

Chenggang Li, Jun Ping Yao, Qu Chen, Bing Li et autres

Abstract Introduction: B7-H3 (CD276) is an immunomodulatory protein of the B7 superfamily molecules, it is overexpressed in a wide range of solid tumors. B7-H3 overexpression often correlates with poor survival and higher tumor grade, it has become an attractive target for the …